A carregar...
Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain (KD) mutation testing have a well consolidated role in the routine management of chronic myeloid leukemia (CML) patients, as they provide precious information for therapeutic decision-making. Molecular response levels...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7760306/ https://ncbi.nlm.nih.gov/pubmed/33261150 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9123865 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|